FindTrial
Sign In

Clozapine in Acute Mania: Safety and Feasibility Evaluation

Feasibility, Saefty and Tolerability of Clozpaine in Acute Mania: A pilot study from central India

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/105016
Enrollment
30
Registered
2026-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F309- Manic episode, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: Nil

Sponsors

AIIMS Bhopal- All India Institute of Medical Sciences Bhopal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age 18y-45y (both inclusive) Of any gender Diagnosed case of acute mania (Bipolar D/O, Schizoaffective D/O) diagnosed by the clinician Patient/NR signed informed written consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients with an baseline absolute neutrophil count less than 1500 Diabetes mellitus epilepsy Diagnosed case of any cardiac disease

Design outcomes

Primary

MeasureTime frame
Adverse effect measured on the scale UKU Time to response Time to remissionTimepoint: Baseline, 1 week, 2-week, 3-week and 4-week—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactROSHAN FAKIRCHAND SUTAR

All India Institute of Medical Science - Bhopal

hasanaftab9751@gmail.com9451193192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026